• 介绍： 鹅去氧胆酸是一种疏水初级胆汁酸，能够活化核受体 FXR，该受体与胆固醇代谢有关。

• 生物活性： Chenodeoxycholic Acid 是一种疏水初级胆汁酸，能够活化核受体 FXR，该受体与胆固醇代谢有关。鹅去氧胆酸（CDCA）和脱氧胆酸（DCA）均能抑制11 beta HSD2，IC50值分别为22mM和38mM，并引起皮质醇依赖性核易位，增加盐皮质激素受体（MR）的转录活性。鹅去氧胆酸能够通过激活膜G蛋白偶联受体（TGR5）依赖途径，诱导细胞周期蛋白d1蛋白和mRNA表达的显著增加，从而刺激Ishikawa细胞的生长。鹅去氧胆酸（CDCA）在培养的人肝母细胞瘤细胞系HepG2中诱导低密度脂蛋白受体mRNA水平约为4倍，高密度脂蛋白辅酶A还原酶和高密度脂蛋白辅酶A合成酶的mRNA水平为2倍。氯去氧胆酸诱导的ISC（≥67%）被布美他尼、Bacl2和囊性纤维化跨膜电导调节器（CFTR）抑制剂cftrinh-172抑制。腺苷酸环化酶抑制剂MDL12330A使鹅去氧胆酸刺激的ISC降低43%，鹅去氧胆酸增加细胞内cAMP浓度。鹅去氧胆酸处理激活c/ebpβ，如其磷酸化、核积累和在hepg2细胞中的表达增加所示。Chenodeoxycholic acid增强含有-1.65-kb GSTA2启动子的构建体的荧光素酶基因转录，该启动子含有C / EBP反应元件（pGL-1651）。鹅去氧胆酸处理激活AMP激活蛋白激酶（AMPK），导致细胞外信号调节激酶1/2（ERK1/2）激活，实验结果证明了使用AMPKα的显性负突变体和化学抑制剂。

• 熔点： 165-167°C

• 沸点： 547.1 °C at 760 mmHg

• 比旋光度： 12 º (c=1, CHCl3)

• 外观： 白色粉末

• 溶解性： 几乎不溶于水，易溶于乙醇、冰乙酸、微溶于氯仿。

• 敏感性： 对光敏感

• 储存条件： 2-8℃

• 注意：部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。

• 29. [IF=5.6] Shengyun Dai et al."Synergistic effect of Euphorbia kansui stir-fried with vinegar and bile acids on malignant ascites effusion through modulation of gut microbiota."Frontiers in Pharmacology.2023; 14: 1249910

• 28. [IF=3.9] Ya-nan Ou-Yang et al."High-salt diet induces dyslipidemia through the SREBP2/PCSK9 pathway in dahl salt-sensitive rats."BIOCHIMIE.2023 Oct;:

• 27. [IF=6.1] Sensen Chi et al."Time-restricted feeding alleviates metabolic implications of circadian disruption by regulating gut hormone release and brown fat activation."Food & Function.2023 Oct;:

• 26. [IF=7.9] Mei-Qi Wang et al."Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress."PHYTOMEDICINE.10.1016/j.phymed.2023.155124

• 25. [IF=4.6] Wei Li et al."Characterization of Metabolic Correlations of Ursodeoxycholic Acid with Other Bile Acid Species through In Vitro Sequential Metabolism and Isomer-Focused Identification."MOLECULES.2023 Jan;28(12):4801

• 24. [IF=4.212] Yingkun Sheng et al."PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes."Molecular Omics.2023 May;:

• 23. [6.911] Yan-Zhen Wang et al."A strategy for screening and identification of new amino acid-conjugated bile acids with high coverage by liquid chromatography-mass spectrometry."ANALYTICA CHIMICA ACTA.2023 Jan;1239:340691

• 22. [7.675] Lei Xu et al."Chenodeoxycholic Acid (CDCA) Promoted Intestinal Epithelial Cell Proliferation by Regulating Cell Cycle Progression and Mitochondrial Biogenesis in IPEC-J2 Cells."Antioxidants.2022 Nov;11(11):2285

• 21. [IF=4.571] Yuanjie Wen et al."The role of the farnesoid X receptor in quadruple anti-tuberculosis drug-induced liver injury."TOXICOLOGY.2022 Jun;476:153256

• 20. [IF=6.558] Yan Cao et al."Widely quasi-quantitative analysis enables temporal bile acids-targeted metabolomics in rat after oral administration of ursodeoxycholic acid."ANALYTICA CHIMICA ACTA. 2022 Jun;1212:339885

• 19. [IF=5.396] Juan Wu et al."Sargassum fusiforme polysaccharide is a potential auxiliary substance for metformin in the management of diabetes."Food Funct. 2022 Feb;:

• 18. [IF=3.935] Runjing Zhang et al."Xiaoyan lidan formula ameliorates α-naphthylisothiocyanate-induced intrahepatic cholestatic liver injury in rats as revealed by non-targeted and targeted metabolomics."J Pharmaceut Biomed. 2020 Feb;179:112966

• 17. [IF=3.935] Song Lin et al."A systemic combined nontargeted and targeted LC-MS based metabolomic strategy of plasma and liver on pathology exploration of alpha-naphthylisothiocyanate induced cholestatic liver injury in mice."J Pharmaceut Biomed. 2019 Jul;171:180

• 16. [IF=3.935] Song Lin et al."A systemic combined nontargeted and targeted LC-MS based metabolomic strategy of plasma and liver on pathology exploration of alpha-naphthylisothiocyanate induced cholestatic liver injury in mice."J Pharmaceut Biomed. 2019 Jul;171:180

• 15. [IF=5.34] Kaihui Zhang et al."A UPLC-MS/MS-based metabolomics analysis of the pharmacological mechanisms of rabdosia serra against cholestasis."Phytomedicine. 2021 Oct;91:153683

• 14. [IF=5.396] Cong Liang et al."Lactiplantibacillus plantarum H-87 prevents high-fat diet-induced obesity by regulating bile acid metabolism in C57BL/6J mice."Food Funct. 2021 May;12(10):4315-4324

• 13. [IF=5.396] Shiming Huang et al."A sulfated polysaccharide from Gracilaria Lemaneiformis regulates cholesterol and bile acid metabolism in high-fat diet mice."Food Funct. 2019 Jun;10(6):3224-3236

• 12. [IF=5.81] Shujing Lv et al."The Study on the Mechanism of Hugan Tablets in Treating Drug-Induced Liver Injury Induced by Atorvastatin."Front Pharmacol. 2021; 12: 683707

• 11. [IF=5.81] Li Peng et al."Detection of Vasodilators From Herbal Components by a Transcriptome-Based Functional Gene Module Reference Approach."Front Pharmacol. 2019 Oct;0:1144

• 10. [IF=3.935] Ziying Liu et al."Promotion of classic neutral bile acids synthesis pathway is responsible for cholesterol-lowing effect of Si-miao-yong-an decoction: Application of LC–MS/MS method to determine 6 major bile acids in rat liver and plasma."J Pharmaceut Bio

• 9. 曹妍,李婷,常安琪,蒋珍珍,于娟,屠鹏飞,宋月林.蛇胆中胆汁酸类化学成分分析[J].中国中药杂志,2021,46(01):130-138.

• 8. 李玮,蒋珍珍,李菡,屠鹏飞,宋青青,于娟,宋月林.利用在线加压溶剂提取-超高效液相色谱-离子阱-飞行时间-质谱法定性分析片仔癀化学成分组[J].色谱,2021,39(05):478-487.

• 7. 曹妍, 宋青青, 李军,等. 牦牛胆中胆汁酸类化学成分分析[J]. 中国中药杂志 2019年44卷12期, 2538-2543页, MEDLINE ISTIC PKU CSCD CA BP, 2019.

• 6. 陈云, 陈劲松, 郁红礼,等. 胆南星发酵制品与混合蒸制品的鉴别研究[J]. 世界中医药, 2019, v.14(02):42-45+50.

• 5. 陈云 郁红礼 吴皓 等. 发酵对胆南星中胆汁酸类成分的影响及胆南星中3种游离胆汁酸含量测定研究[J]. 中国中药杂志 2018 43(22):99-103.

• 4. 陈江宁, 单国顺, 刘晓瑜,等. 胆南星辅料成分分析及其清热作用[J]. 中国现代中药 2016年18卷7期, 837-840页, ISTIC CA, 2016.

• 3. 席晓志, 李佳, 郭莎莎,等. 鹅去氧胆酸的大孔树脂纯化工艺优化及其降血脂活性[J]. 现代食品科技, 2018, 034(008):123-129.

• 2. 赵启苗, 单国顺, 陈江宁,等. 胆南星质量评价方法初探[J]. 中国实验方剂学杂志, 2017(06):28-31.

• 1. 陈江宁 单国顺 赵启苗 等. 不同胆汁制胆南星中胆酸类成分及其解热作用比较[J]. 现代药物与临床 2017 32(004):567-571.

输入产品批号：

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *